In the relentless battle against cancer, Werewolf Therapeutics emerges as a beacon of innovation, pioneering a revolutionary approach to immunotherapy that harnesses the body’s innate immune system with remarkable precision. Their proprietary PREDATOR™ platform empowers the development of conditionally activated molecules, known as INDUKINE™, which selectively engage immune cells within the tumor microenvironment, leaving healthy tissues unharmed. This targeted strategy addresses the limitations of conventional proinflammatory therapies that often cause widespread inflammation, leading to unwanted side effects.

Werewolf’s Differentiated Approach: Unleashing Targeted Proinflammatory Mechanisms

Werewolf Therapeutics' proprietary PREDATOR™ platform empowers the development of conditionally activated molecules, known as INDUKINE™, that selectively engage immune cells within the tumor microenvironment, leaving healthy tissues unscathed. This targeted strategy addresses the limitations of conventional proinflammatory therapies, which often induce widespread inflammation leading to unwanted side effects.

The Science Behind INDUKINE™ Molecules

The brilliance of Werewolf’s INDUKINE™ molecules lies in their ability to remain inactive until they encounter the unique conditions of the tumor microenvironment. This selectivity is achieved through a masterful understanding of the molecular interactions that govern immune activation.

Specifically, INDUKINE™ molecules are engineered with masking peptides that prevent their interaction with immune receptors until they reach the tumor microenvironment. Once within the tumor, the masking peptides are cleaved by enzymes, exposing the active form of the INDUKINE™ molecule and triggering a potent immune response against cancer cells.

Compelling Advantages of Werewolf’s Approach

Werewolf’s differentiated approach offers several compelling advantages over conventional immunotherapy methods:

• Enhanced Tumor Targeting: INDUKINE™ molecules selectively engage immune cells within the tumor microenvironment, minimizing exposure to healthy tissues and reducing the risk of adverse side effects.
• Potent Immune Activation: INDUKINE™ molecules trigger a robust immune response against cancer cells, effectively eradicating tumors and preventing their recurrence.
• Broad Therapeutic Potential: INDUKINE™ molecules can be tailored to target a wide range of cancers, offering a versatile platform for treating various malignancies.
• Reduced Adverse Effects: By minimizing exposure to healthy tissues, INDUKINE™ molecules significantly reduce the risk of severe side effects often associated with conventional proinflammatory therapies.

Clinical Pipeline: Transforming Cancer Immunotherapy

Werewolf boasts a promising clinical pipeline of INDUKINE™ molecules in various stages of development, demonstrating their potential to revolutionize cancer immunotherapy.

• WTX-124: An INDUKINE™ molecule targeting the interleukin-2 (IL-2) receptor, currently in Phase 1 clinical trials for the treatment of solid tumors.
• WTX-330: An INDUKINE™ molecule targeting the interleukin-12 (IL-12) receptor, currently in preclinical development for the treatment of solid tumors.
• Additional INDUKINE™ molecules: Werewolf is continuously expanding its pipeline with INDUKINE™ molecules targeting other key immune receptors, broadening the therapeutic potential of their platform.

Experienced Leadership: Navigating the Path to Success

Werewolf’s leadership team comprises seasoned experts in oncology, immunology, and drug development, bringing deep expertise to guide the company’s growth.

• Dr. Andrew Affanasie, Ph.D., Co-Founder and CEO: A renowned scientist with extensive experience in cancer immunotherapy and drug development.
• Dr. Cynthia Seidel-Dugan, Ph.D., Chief Scientific Officer: A leading expert in immunology and protein engineering, responsible for the development of the PREDATOR™ platform.
• Mr. Andrew Stevenson, Chief Financial Officer: A seasoned financial executive with a proven track record of success in the biopharmaceutical industry.

Strong Intellectual Property: Safeguarding Innovation

Werewolf holds a robust intellectual property portfolio, safeguarding its competitive edge in the field of conditionally activated therapeutics.

• Patents covering the PREDATOR™ platform and INDUKINE™ molecules.
• Exclusive licensing agreements with leading research institutions.
• Ongoing research collaborations to expand the intellectual property landscape.

Investment Potential: A Beacon of Hope in the Fight Against Cancer

With its groundbreaking technology and unwavering commitment to improving patient outcomes, Werewolf Therapeutics presents a compelling investment opportunity for several reasons:

• Promising Clinical Pipeline: Werewolf boasts a promising clinical pipeline of INDUKINE™ molecules in various stages of development, demonstrating their potential to revolutionize cancer immunotherapy.
• Experienced Leadership: Werewolf’s leadership team comprises seasoned experts in oncology, immunology, and drug development, bringing deep expertise to guide the company’s growth.
• Strong Intellectual Property: Werewolf holds a robust intellectual property portfolio, safeguarding its competitive edge in the field of conditionally activated therapeutics.
• Untapped Market Potential: The market for cancer immunotherapy is expected to reach a value of $264 billion by 2030.